All Immunotherapy articles – Page 5
-
News
Improving the effectiveness of immunotherapy for glioblastoma
Researchers utilised AI to identify genes that reprogramme GBM cancer cells into dendritic cells within the tumour.
-
WebinarUnprecedented fragment-based screening using Spectral Shift for GPCRs
In this webinar, we will present how challenging recombinant protein such as GPCRs are produced and characterised and how biophysics participates in GPCRs hit finding and hit confirmation.
-
ArticleTranslating ‘nature’s cues’ into breakthrough immunotherapies
Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming ...
-
ArticleHow MMR-deficient colorectal cancers regulate their growth
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
-
ArticleA T cell receptor immunotherapy against a novel target
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
-
News
Macrophage-mediated phagocytosis: treating solid tumours
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
-
NewsReprogramming immune-suppressive macrophages in tumours
A novel drug, JHU083, turns into its active, glutamine-blocking form inside tumours, shrinking prostate and bladder cancers in mice.
-
ArticleImproving treatment responses to solid tumours with trispecific TCEs
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
-
WebinarImmunotherapy advancements: transforming cancer treatment
In recent years, immunotherapy has emerged as a revolutionary approach in cancer treatment, harnessing the power of the immune system to combat cancer cells. This webinar will explore the latest advancements in immunotherapy research, highlighting breakthroughs, challenges, and future directions in the field. Participants will gain insights, including immune checkpoint ...
-
ArticleUtilising engineered peptides for immunotherapy
In this Q&A, Dr DaeYong Lee discusses how a new method for building up natural immune response could lead to new immunotherapy drugs with safer toxicity profiles.
-
NewsHow tumours prevent formation of immune responses
Scientists found that preventing the effects of prostaglandin E2 could be an effective therapy to overcome tumour defence.
-
NewsExplaining uveal melanoma’s resistance to conventional immunotherapies
Researchers have developed a new tool called ‘Uveal Melanoma Immunogenic Score’ to predict which patients will respond to adoptive therapy.
-
ArticleThe immune system’s role in lung cancer risk
In this Q&A, Ichan Mount Siani researchers Dr Diego Chowell and Dr Robert Samstein share their new insights about the associations between human leukocyte antigen (HLA) class II loci and lung cancer risk.
-
NewsFOXO1 improves survival and function of CAR T cells
Evidence indicating that FOXO1 plays a unique role in promoting T cell longevity could result in more effective CAR T cell therapies.
-
NewsLink identified between bacteria and cancer treatment efficacy
Researchers mapped the bacteria present in over 4000 metastatic tumour biopsies, which could enable the exploration of new treatments.
-
ArticleBreaking resistance – the future of immunotherapy in oncology
In this episode, we explore the current status and potential solutions to addressing major hurdles in oncology.
-
NewsNew strategies to overcome CAR T-cell resistance in AML cells
Pharmacological concomitant therapies or further genetic improvement of CAR T-cells can increase their effectiveness against TP53-mutant AML cells.
-
Article
The advancement of drug-free immunotherapy
Researchers have created a neutrophil therapy, involving micropatches that maintain the cells’ antitumour state, which could offer significant clinical and commercial value.
-
NewsEpstein-Barr virus: new targets for vaccine design and treatment
A lab generated monoclonal antibody prevented EBV infection and EBV lymphomas in rodent models and could have future clinical applications.
-
NewsNew insights into PD-1 formation could greatly improve treatments
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.